The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...
With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a 200 mg Benlysta autoinjector for children aged 5 years and ...
The U.S. Food and Drug Administration has approved GlaxoSmithKline's 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...
The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...
The 200mg single-dose prefilled autoinjector allows pediatric patients to receive LN treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab), ...
The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...
The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...
The U.S. Food & Drug Administration (FDA) has granted approval for a novel and less invasive belimumab (Benlysta®) treatment for children with systemic lupus erythematosus (SLE) ages five years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results